Seroatlas · Human Serome Atlas

KRAS

GTPase KRas

Also known as: K-Ras4B, KRAS1, KRAS2, RASK_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P01116
Gene
KRAS
Ensembl
ENSG00000133703
Chromosome
12
Canonical length
189 aa
Protein class
Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, RAS pathway related proteins
Subcellular location
Cytosol

OverviewNCBI Gene

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

189 residues, UniProt reviewed canonical sequence.

>P01116|KRAS
     1  MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG
    61  QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHHYREQI KRVKDSEDVP MVLVGNKCDL
   121  PSRTVDTKQA QDLARSYGIP FIETSAKTRQ RVEDAFYTLV REIRQYRLKK ISKEEKTPGC
   181  VKIKKCIIM

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against KRAS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.29
Highest tissue expression
21 nTPM

Expression across tissuesHPA

Tissue

  • rectum: 21 nTPM
  • colon: 20 nTPM
  • stomach: 19 nTPM
  • cerebral cortex: 17 nTPM
  • small intestine: 17 nTPM
  • esophagus: 17 nTPM

Single-cell type

  • neutrophils: 509 nCPM
  • esophageal apical cells: 504 nCPM
  • neutrophil progenitors: 198 nCPM
  • colonocytes: 193 nCPM
  • syncytiotrophoblasts: 190 nCPM
  • suprabasal keratinocytes: 169 nCPM

Immune cell

  • basophil: 32 nTPM
  • non-classical monocyte: 22 nTPM
  • neutrophil: 18 nTPM
  • intermediate monocyte: 16 nTPM
  • eosinophil: 14 nTPM
  • naive CD4 T-cell: 13 nTPM

Brain region

  • hypothalamus: 27 nTPM
  • cerebral cortex: 26 nTPM
  • basal ganglia: 26 nTPM
  • cerebellum: 24 nTPM
  • thalamus: 22 nTPM
  • hippocampal formation: 22 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about KRAS.

Disease | AllUniProt

Conditions KRAS is implicated in, by any mechanism.

Disease | GeneticClinVar

96 pathogenic / likely-pathogenic of 547 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on KRAS was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.24
gnomAD pLI
0
gnomAD missense Z
2.32
DepMap mean gene effect
-0.56
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 9% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of KRAS in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads KRAS as an antibody target. Whether an autoantibody or antibody against KRAS could matter depends on whether native KRAS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

KRAS is annotated at the cell surface, where native KRAS is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label KRAS as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/KRAS. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...